Elcan Patricia F
Known title: 10% OwnerCIK: 0001433376
Elcan Patricia F's purchase track record
Elcan Patricia F has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/25/2022 | HCA | $65K | +6.2% | +33.5% | +1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| HCA | ▼ Sell | Other | 36,629,188 | — | 2/6/2026 | View on chart |
| HCA | ▼ Sell | Other | 36,557,141 | — | 2/6/2026 | View on chart |
| HCA | ▼ Sell | Other | 244,626 | $88.4M | 10/30/2024 | View on chart |
| HCA | ▼ Sell | Other | 138,000 | $49.9M | 10/30/2024 | View on chart |
| HCA | ▼ Sell | Other | 638,574 | $230.9M | 10/30/2024 | View on chart |
| HCA | ▼ Sell | Other | 138,000 | $49.9M | 10/30/2024 | View on chart |
| HCA | ▼ Sell | Other | 244,626 | $88.4M | 10/30/2024 | View on chart |
| HCA | ▼ Sell | Other | 638,574 | $230.9M | 10/30/2024 | View on chart |
| HCA | ▲ Buy | Open Market | 325 | $65K | 7/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns
HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.